Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study
Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with prostate cancer between 1990 and 1996 and...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2009-03, Vol.100 (6), p.888-893 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 893 |
|---|---|
| container_issue | 6 |
| container_start_page | 888 |
| container_title | British journal of cancer |
| container_volume | 100 |
| creator | Berney, D M Gopalan, A Kudahetti, S Fisher, G Ambroisine, L Foster, C S Reuter, V Eastham, J Moller, H Kattan, M W Gerald, W Cooper, C Scardino, P Cuzick, J |
| description | Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with prostate cancer between 1990 and 1996 and treated conservatively. Ki-67 expression was assessed immunohistochemically, in two laboratories, by two different scoring methods and the results compared with cancer-specific and overall survival. The power of the biomarker was compared with Gleason score and initial serum prostate-specific antigen (PSA). Both methods showed that Ki-67 provided additional prognostic information beyond that available from Gleason score and PSA: for the semi-quantitative method, Δ
χ
2
(1 d.f.)=24.6 (
P |
| doi_str_mv | 10.1038/sj.bjc.6604951 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2661778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1662771871</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-7c33c9f254607a365eeb1d912a927e637007634e43af33e46dcd711d29f490093</originalsourceid><addsrcrecordid>eNp1kUtvEzEUhUcIRENhyw5kIcFuUj8mdswCqaqgICrBoqwtx3On9WjGDr6eSPk9_FEckqY8xMqy7neuj8-pqueMzhkVyzPs56vezaWkjV6wB9WMLQSv2ZKrh9WMUqpqqjk9qZ4g9uWq6VI9rk6Y5losqZpVPz77WipiQ0vilF0cgfhA3OCDd3YYtmSI5fQILVmniNlmIM4GB-ltEdlhix5J7IiLASFtbPYbKKqcoJD_aMi6ABAyki7FkeRbINfJBqzP82BD9o58vRNcpjitCeap3T6tHnV2QHh2OE-rbx_eX198rK--XH66OL-q3YKqXCsnhNMdXzSSKivkAmDFWs241VyBFKqkIUUDjbCdENDI1rWKsZbrrtElGnFavdvvXU-rEVpXjCY7mHXyo01bE603f06CvzU3cWO4lEypZVnw5rAgxe8TYDajRwdD-RvECY1UtOGU71569RfYxymVONFwrrVuGrrbNt9DrmSCCbqjE0bNrnyDvSnlm0P5RfDyd__3-KHtArw-ABZLq12J3nk8cpwVTP6yd7bnsIzCDaR7e_99-sVeEWyeEhxX3s1_Atax1aE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229994408</pqid></control><display><type>article</type><title>Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study</title><source>MEDLINE</source><source>Nature</source><source>SpringerNature Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Berney, D M ; Gopalan, A ; Kudahetti, S ; Fisher, G ; Ambroisine, L ; Foster, C S ; Reuter, V ; Eastham, J ; Moller, H ; Kattan, M W ; Gerald, W ; Cooper, C ; Scardino, P ; Cuzick, J</creator><creatorcontrib>Berney, D M ; Gopalan, A ; Kudahetti, S ; Fisher, G ; Ambroisine, L ; Foster, C S ; Reuter, V ; Eastham, J ; Moller, H ; Kattan, M W ; Gerald, W ; Cooper, C ; Scardino, P ; Cuzick, J ; for The Trans-Atlantic Prostate Group</creatorcontrib><description>Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with prostate cancer between 1990 and 1996 and treated conservatively. Ki-67 expression was assessed immunohistochemically, in two laboratories, by two different scoring methods and the results compared with cancer-specific and overall survival. The power of the biomarker was compared with Gleason score and initial serum prostate-specific antigen (PSA). Both methods showed that Ki-67 provided additional prognostic information beyond that available from Gleason score and PSA: for the semi-quantitative method, Δ
χ
2
(1 d.f.)=24.6 (
P
<0.0001), overall survival
χ
2
=20.5 (
P
<0.0001), and for the quantitative method, Δ
χ
2
(1 d.f.)=15.1 (
P
=0.0001), overall survival
χ
2
=10.85 (
P
=0.001). Ki-67 is a powerful biomarker in localised prostate cancer and adds to a model predicting the need for radical or conservative therapy. As it is already in widespread use in routine pathology, it is confirmed as the most promising biomarker to be applied into routine practice.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6604951</identifier><identifier>PMID: 19293807</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Aged ; Antigens ; Biological and medical sciences ; Biomarkers ; Biomedical and Life Sciences ; Biomedicine ; Biopsy ; Cancer Research ; Cancer therapies ; Cell cycle ; Clinical Study ; Drug Resistance ; Epidemiology ; Humans ; Immunohistochemistry ; Ki-67 Antigen - analysis ; Laboratories ; Lymphatic system ; Male ; Medical prognosis ; Medical research ; Medical sciences ; Metastasis ; Middle Aged ; Molecular Medicine ; Nephrology. Urinary tract diseases ; Oncology ; Pathology ; Patients ; Preventive medicine ; Prognosis ; Prostate cancer ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - therapy ; Surveillance ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>British journal of cancer, 2009-03, Vol.100 (6), p.888-893</ispartof><rights>The Author(s) 2009</rights><rights>2009 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Mar 24, 2009</rights><rights>Copyright © 2009 Cancer Research UK 2009 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-7c33c9f254607a365eeb1d912a927e637007634e43af33e46dcd711d29f490093</citedby><cites>FETCH-LOGICAL-c507t-7c33c9f254607a365eeb1d912a927e637007634e43af33e46dcd711d29f490093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661778/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661778/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2727,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21938629$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19293807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berney, D M</creatorcontrib><creatorcontrib>Gopalan, A</creatorcontrib><creatorcontrib>Kudahetti, S</creatorcontrib><creatorcontrib>Fisher, G</creatorcontrib><creatorcontrib>Ambroisine, L</creatorcontrib><creatorcontrib>Foster, C S</creatorcontrib><creatorcontrib>Reuter, V</creatorcontrib><creatorcontrib>Eastham, J</creatorcontrib><creatorcontrib>Moller, H</creatorcontrib><creatorcontrib>Kattan, M W</creatorcontrib><creatorcontrib>Gerald, W</creatorcontrib><creatorcontrib>Cooper, C</creatorcontrib><creatorcontrib>Scardino, P</creatorcontrib><creatorcontrib>Cuzick, J</creatorcontrib><creatorcontrib>for The Trans-Atlantic Prostate Group</creatorcontrib><title>Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with prostate cancer between 1990 and 1996 and treated conservatively. Ki-67 expression was assessed immunohistochemically, in two laboratories, by two different scoring methods and the results compared with cancer-specific and overall survival. The power of the biomarker was compared with Gleason score and initial serum prostate-specific antigen (PSA). Both methods showed that Ki-67 provided additional prognostic information beyond that available from Gleason score and PSA: for the semi-quantitative method, Δ
χ
2
(1 d.f.)=24.6 (
P
<0.0001), overall survival
χ
2
=20.5 (
P
<0.0001), and for the quantitative method, Δ
χ
2
(1 d.f.)=15.1 (
P
=0.0001), overall survival
χ
2
=10.85 (
P
=0.001). Ki-67 is a powerful biomarker in localised prostate cancer and adds to a model predicting the need for radical or conservative therapy. As it is already in widespread use in routine pathology, it is confirmed as the most promising biomarker to be applied into routine practice.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biopsy</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Clinical Study</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Ki-67 Antigen - analysis</subject><subject>Laboratories</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Patients</subject><subject>Preventive medicine</subject><subject>Prognosis</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Surveillance</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kUtvEzEUhUcIRENhyw5kIcFuUj8mdswCqaqgICrBoqwtx3On9WjGDr6eSPk9_FEckqY8xMqy7neuj8-pqueMzhkVyzPs56vezaWkjV6wB9WMLQSv2ZKrh9WMUqpqqjk9qZ4g9uWq6VI9rk6Y5losqZpVPz77WipiQ0vilF0cgfhA3OCDd3YYtmSI5fQILVmniNlmIM4GB-ltEdlhix5J7IiLASFtbPYbKKqcoJD_aMi6ABAyki7FkeRbINfJBqzP82BD9o58vRNcpjitCeap3T6tHnV2QHh2OE-rbx_eX198rK--XH66OL-q3YKqXCsnhNMdXzSSKivkAmDFWs241VyBFKqkIUUDjbCdENDI1rWKsZbrrtElGnFavdvvXU-rEVpXjCY7mHXyo01bE603f06CvzU3cWO4lEypZVnw5rAgxe8TYDajRwdD-RvECY1UtOGU71569RfYxymVONFwrrVuGrrbNt9DrmSCCbqjE0bNrnyDvSnlm0P5RfDyd__3-KHtArw-ABZLq12J3nk8cpwVTP6yd7bnsIzCDaR7e_99-sVeEWyeEhxX3s1_Atax1aE</recordid><startdate>20090324</startdate><enddate>20090324</enddate><creator>Berney, D M</creator><creator>Gopalan, A</creator><creator>Kudahetti, S</creator><creator>Fisher, G</creator><creator>Ambroisine, L</creator><creator>Foster, C S</creator><creator>Reuter, V</creator><creator>Eastham, J</creator><creator>Moller, H</creator><creator>Kattan, M W</creator><creator>Gerald, W</creator><creator>Cooper, C</creator><creator>Scardino, P</creator><creator>Cuzick, J</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090324</creationdate><title>Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study</title><author>Berney, D M ; Gopalan, A ; Kudahetti, S ; Fisher, G ; Ambroisine, L ; Foster, C S ; Reuter, V ; Eastham, J ; Moller, H ; Kattan, M W ; Gerald, W ; Cooper, C ; Scardino, P ; Cuzick, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-7c33c9f254607a365eeb1d912a927e637007634e43af33e46dcd711d29f490093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biopsy</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Clinical Study</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Ki-67 Antigen - analysis</topic><topic>Laboratories</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Patients</topic><topic>Preventive medicine</topic><topic>Prognosis</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Surveillance</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berney, D M</creatorcontrib><creatorcontrib>Gopalan, A</creatorcontrib><creatorcontrib>Kudahetti, S</creatorcontrib><creatorcontrib>Fisher, G</creatorcontrib><creatorcontrib>Ambroisine, L</creatorcontrib><creatorcontrib>Foster, C S</creatorcontrib><creatorcontrib>Reuter, V</creatorcontrib><creatorcontrib>Eastham, J</creatorcontrib><creatorcontrib>Moller, H</creatorcontrib><creatorcontrib>Kattan, M W</creatorcontrib><creatorcontrib>Gerald, W</creatorcontrib><creatorcontrib>Cooper, C</creatorcontrib><creatorcontrib>Scardino, P</creatorcontrib><creatorcontrib>Cuzick, J</creatorcontrib><creatorcontrib>for The Trans-Atlantic Prostate Group</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berney, D M</au><au>Gopalan, A</au><au>Kudahetti, S</au><au>Fisher, G</au><au>Ambroisine, L</au><au>Foster, C S</au><au>Reuter, V</au><au>Eastham, J</au><au>Moller, H</au><au>Kattan, M W</au><au>Gerald, W</au><au>Cooper, C</au><au>Scardino, P</au><au>Cuzick, J</au><aucorp>for The Trans-Atlantic Prostate Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2009-03-24</date><risdate>2009</risdate><volume>100</volume><issue>6</issue><spage>888</spage><epage>893</epage><pages>888-893</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with prostate cancer between 1990 and 1996 and treated conservatively. Ki-67 expression was assessed immunohistochemically, in two laboratories, by two different scoring methods and the results compared with cancer-specific and overall survival. The power of the biomarker was compared with Gleason score and initial serum prostate-specific antigen (PSA). Both methods showed that Ki-67 provided additional prognostic information beyond that available from Gleason score and PSA: for the semi-quantitative method, Δ
χ
2
(1 d.f.)=24.6 (
P
<0.0001), overall survival
χ
2
=20.5 (
P
<0.0001), and for the quantitative method, Δ
χ
2
(1 d.f.)=15.1 (
P
=0.0001), overall survival
χ
2
=10.85 (
P
=0.001). Ki-67 is a powerful biomarker in localised prostate cancer and adds to a model predicting the need for radical or conservative therapy. As it is already in widespread use in routine pathology, it is confirmed as the most promising biomarker to be applied into routine practice.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>19293807</pmid><doi>10.1038/sj.bjc.6604951</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2009-03, Vol.100 (6), p.888-893 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2661778 |
| source | MEDLINE; Nature; SpringerNature Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Aged Antigens Biological and medical sciences Biomarkers Biomedical and Life Sciences Biomedicine Biopsy Cancer Research Cancer therapies Cell cycle Clinical Study Drug Resistance Epidemiology Humans Immunohistochemistry Ki-67 Antigen - analysis Laboratories Lymphatic system Male Medical prognosis Medical research Medical sciences Metastasis Middle Aged Molecular Medicine Nephrology. Urinary tract diseases Oncology Pathology Patients Preventive medicine Prognosis Prostate cancer Prostatic Neoplasms - diagnosis Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - therapy Surveillance Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A06%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ki-67%20and%20outcome%20in%20clinically%20localised%20prostate%20cancer:%20analysis%20of%20conservatively%20treated%20prostate%20cancer%20patients%20from%20the%20Trans-Atlantic%20Prostate%20Group%20study&rft.jtitle=British%20journal%20of%20cancer&rft.au=Berney,%20D%20M&rft.aucorp=for%20The%20Trans-Atlantic%20Prostate%20Group&rft.date=2009-03-24&rft.volume=100&rft.issue=6&rft.spage=888&rft.epage=893&rft.pages=888-893&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6604951&rft_dat=%3Cproquest_pubme%3E1662771871%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229994408&rft_id=info:pmid/19293807&rfr_iscdi=true |